# EDGAR Filing Document

**Accession Number:** 0000313143
**File Stem:** 0000313143-26-000023
**Filing Date:** 2026-5
**Character Count:** 5162
**Document Hash:** 701ff02ab54e57a134334b3f1e9a6979
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000313143-26-000023.hdr.sgml**: 20260501

**ACCESSION NUMBER**: 0000313143-26-000023

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260427

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20260501

**DATE AS OF CHANGE**: 20260501

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HAEMONETICS CORP
- **CENTRAL INDEX KEY:** 0000313143
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 042882273
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 0328

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-14041
- **FILM NUMBER:** 26932813

**BUSINESS ADDRESS:**
- **STREET 1:** 125 SUMMER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 7818487100

**MAIL ADDRESS:**
- **STREET 1:** 125 SUMMER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

?xml version='1.0' encoding='ASCII'? hae-20260427

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 27, 2026**

**HAEMONETICS CORPORATION** 

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Massachusetts** | **001-14041** | **04-2882273** |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (I.R.S. Employer<br>Identification No.) |

---

**125 Summer Street**

**Boston, MA 02110** 

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **781-848-7100** 

(Former name or former address, if changed since last report.)

---

| | |
|:---|:---|
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, $.01 par value per share | HAE | New York Stock Exchange |

---

---

| |
|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| Emerging Growth Company |
| ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |

---

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the "Company") that he will not stand for re-election at the Company's 2026 Annual Meeting of Shareholders (the "2026 Annual Meeting"). Mr. Dockendorff has served as a member of the Board of Directors (the "Board") of the Company since 2014 and currently serves as a member of the Audit Committee and the Governance and Compliance Committee. Mr. Dockendorff will continue to serve as a director and in his committee roles until the 2026 Annual Meeting. Mr. Dockendorff's decision not to stand for re-election at the 2026 Annual Meeting is not the result of any disagreement with the Company.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **HAEMONETICS CORPORATION** | **HAEMONETICS CORPORATION** |
| May 1, 2026 | By: | /s/ Christopher A. Simon |
|  | Name: | Christopher A. Simon |
|  | Title: | President and Chief Executive Officer |

---